门冬胰岛素在青少年1型糖尿病胰岛素泵中的应用

目的:评价新型速效胰岛素类似物门冬胰 岛素注射液在中国青少年1型糖尿病胰岛素泵治疗 中的有效性和安全性并与常规人胰岛素泵治疗比 较。方法:10例正在使用胰岛素泵的青少年1型糖 尿病病人,年龄(13±s3)a,进行4wk的纳入期(继 续常规人胰岛素治疗)和8wk的治疗期(改用门冬 胰岛素治疗),共12wk的研究,观察治疗前后餐后 2h血糖(PBG)、空腹血糖(FBG)、糖化血红蛋白 (HbA1c)和不良反应。结果:治疗8wk后,FBG, PBG和HbA1c分别由(9±3)mmol·L-1,(11.6± 2.7)mmol·L-1和(9.1±2.0)%下降至(6± 3)mmol·L-1,(7±3)mmol·L-1和(7.6± 1.2)%。PBG和HbA1c与治疗前比较差异有非常 显著和显著意(P<0.01,P<0.05)。治疗过程中 低血糖事件无明显增加。结论:门冬胰岛素能有效 降低青少年1型糖尿病病人PBG和HbA1c,无明显 不良反应,是目前胰岛素泵治疗中满意的胰岛素类 型。

Efficacy and safety of insulin aspart used in continuous subcutaneous insulin infusion therapy in children and adolescences with type 1 diabetes

AIM: To evaluate the efficacy and safety of a rapid-acting insulin analog insulin aspart in patients with type 1 diabetes undergoing continuous subcutaneous insulin infusion (CSII) therapy and compare with regular human insulin. METHODS: Ten patients with type 1 diabetes ,aged(13±s 3)a, received CSII therapy with regular human insulin as routine for 4 wk, and then with insulin aspart for treating stage of 8 wk. The levels of fasting blood glucose (FBG), 2 h postprandial blood glucose (PBG) and glycosylated hemoglobin (HbA 1c) were observed before and after the insulin aspart treatment. At the same time, the adverse reactions occurred during treatment were observed. RESULTS: After treated with insulin aspart, FBG level from (9±3)to (6±3) mmol·L -1, PBG level from (11.6±2.7) to (7±3)mmol·L -1 and HbA 1c level from (9.1±2.0)% to(7.6± 1.2)%, P<0.05.After receiving insulin aspart, patients showed no more hypoglycemia. CONCLUTIONS: Insulin aspart is effective in controlling the FBG, PBG and HbA 1c with rare adverse reaction and also a good choice for type 1 diabetes with CSII therapy.